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Abstract 
There is debate as to whether PCI with drug-eluting stents or CABG is the best procedure for 
subjects with type 2 diabetes and coronary artery disease requiring revascularization.  There is some 
evidence that following these procedures there is less further revascularization with CABG than PCI 
in subjects with diabetes.  Two recent studies; the FREEDOM (Future Revascularization Evaluation in 
patients with Diabetes mellitus: Optimal Management of Multivessel Disease) trial, and a trial using 
a real world diabetic population from a Registry, have shown that the benefits of CABG over PCI in 
subjects with type 2 diabetes extends to lower rates of death and myocardial infarct, in addition to 
lower rates of revascularization.  However, the rates of stroke may be higher with CABG than PCI 
with drug-eluting stents in this population.  Thus, if CABG is going to be preferred to PCI in subjects 
with type 2 diabetes and multivessel coronary disease, consideration should be given to how to 
reduce the rates of stroke with CABG. 
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1. Introduction 
Coronary artery disease is a major cause of morbidity and mortality in subjects with diabetes, with 
25% of coronary revascularization in the US occurring in subjects with diabetes [1].  In 2005, Flaherty 
& Davidson reviewed the randomized controlled trials comparing CABG surgery and PCI in subjects 
with diabetes, and showed a mortality benefit for CABG over balloon-only PCI [1].  However, CABG 
had not been clearly demonstrated to better than stent-assisted PCI, or to be the most effective in 
subjects with diabetes at high-risk for CABG [1].  Also, in 2005, restenosis after PCI was causing 
higher revascularization rates than with CABG in subjects with diabetes [1].    
In 2010, two studies comparing CABG and PCI in subjects with diabetes were reported, and showed 
lower revascularization rates with CABG than PCI.  One of these studies was the CARDia (Coronary 
Artery Revascularization in Diabetes) trial, which enrolled 510 subjects with diabetes and mutivessel 
or complex single vessel coronary disease to either CARG or PCI with bare stents initially and then 
sirolimus drug-eluting stents [2].  After one year, PCI or PCI with drug-eluting stents were noninferior 
to CABG in causing the composite rate of death, myocardial infarction and stroke [kapur10].  
However, when revascularization was added to this primary outcome the rate was higher with PCI 
than with CABG (19.3% vs 11.3%), as the revascularization rates after these procedures were 11.8% 
and 2.0%, respectively [2]. 
The SYNTAX (SYNergy between percutaneous coronary intervention with TAXus and cardiac surgery) 
study differed from CARDia in using paclitaxel-eluting rather than sirolimus-eluting stents, but did 
compare CABG and PCI in 452 subjects with diabetes [3].  As in CARDia, the composite of death, 
myocardial infaction and stroke was similar in both groups after one year, but once revascularization 
was added, the rate was higher with PCI than with CABG (26.0% vs 14.2%) due to revascularization 
rates after these procedures of 20.3% and 3.2%, respectively [3].  After three years in SYNTAX, the 
composite of death, myocardial infarction and stroke was still similar in both groups, and the rate of 
revascularization remained higher with PCI than with CABG (28.0% vs 12.9%) [4]. 
As CARDia and SYNTAX were relatively small studies, they were not powered to detect significant 
differences in the composite of death, myocardial infarction, and death between CABG and PCI in 
subjects with diabetes [5].  Meta-analysis including the randomized CARDia and SYNTAX trials and 9 
non-randomized studies comparing drug-eluting stents to CABG, in subjects with diabetes, has also 
shown that revascularization is greater with PCI than CABG [5].  However, the composite of death, 
myocardial infarction and cerebral vascular attack was lower with PCI than CABG in this meta-
analysis [5].  However, the inclusion of non-randomised studies is major limitation to this meta-
analysis.  Thus, larger clinical studies were still necessary to clarify the effects of CABG and PCI in 
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subjects with diabetes and coronary artery disease, on mortality and morbidity.  Two recent studies 
have clarified that the benefits of CABG over PCI in subjects with type 2 diabetes does extend to 
lower rates of death and myocardial infarct; the first of these studies is the FREEDOM trial, which is 
discussed in Section 2, and the second is in a real world diabetic population from a Registry, and is 
discussed in Section 3. 
2. The FREEDOM clinical trial 
2.1 Methods and results 
The methods and results for the FREEDOM open-label, randomized superiority trial of PCI versus 
CABG clinical trial [6,7] are combined in this section.  FREEDOM was a collaboration between 
cardiologists and cardiac surgeons in 5 centres in the US and one in Canada.  In FREEDOM, 3309 
subjects with type 2 diabetes, and angiographically confirmed multivessel coronary artery disease (≥ 
70% lesions in ≥ 2 major epicardial vessels and ≥ 2 separate coronary artery territories), were eligible 
for the study [6].  The angiographic characteristics had to be amenable for PCI and CABG, and the 
indication for revascularization based upon symptoms of angina, and /or objective evidence of 
myocardial ischemia [6].  Among the subjects ineligible were those with severe congestive heart 
failure, prior PCI or stroke within last 6 months, or acute ST-elevation myocardial infarction with 72 
hours [6]. 
Consent was obtained from 1900 of the eligible 3309 subjects (57.3%).  The consenting subjects had 
a mean age of 63.1 years, 71% were men, and 83% of the patients had three-vessel disease.  About 
25% of these subjects with type 2 diabetes had a history of myocardial infarction, and 30% had a 
recent acute coronary syndrome, and insulin was used in about a third of the subjects.  
Subjects with type 2 diabetes, and in need of revascularization, were randomized on a 1:1 basis to 
either CABG (947 subjects) or PCI (953).  For PCI, sirolimus-eluting-eluting stents were used in 51%, 
paclitaxel-eluting stents in 43%, and new generation stents in the others.   
The primary outcome was a composite of death consisting of any cause, nonfatal myocardial 
infarction, or nonfatal stroke.  Initially, the analysis favored PCI, long-term outcomes were better 
with CABG.  Thus, after 30 days, the primary outcome had occurred in significantly fewer subjects in 
the PCI group (26 of 953) than in the CABG group (42 of 947).  However, by 2 years, the primary 
outcome had occurred in significantly fewer subjects in the CABG group than the PCI group (108 vs 
121), and this benefit in favour of CABG over PCI was maintained after 5 years (146 vs 200).  
For the components of the primary outcome, CABG significantly reduced death from any cause and 
myocardial infarction compared to PCI, whereas PCI was superior to CABG at reducing stroke in 
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subjects with type 2 diabetes.  Thus, after 5 years, death from any cause occurred in 18.7% and 
26.6% of CABG and PCI subjects, myocardial infarction in 10.9% and 16.3%, and stroke occurred in 
5.2% and 2.4% of subjects, respectively.  
One of the secondary outcomes was cardiovascular deaths, and after 5 years the rate was lower 
with CABG (6.8%) than with PCI (10.9%).  Another secondary outcome was the rate of major adverse 
cardiovascular and cerebrovascular events, and consisted of the primary outcome plus 
revascularizations. This secondary outcome favored CABG over PCI after one year (11.8% vs 16.8%), 
mainly because there were less revascularizations with CABG than PCI (4.8% vs 12.6%). 
Subgroup analysis showed the benefit of CABG over PCI was consistent for sex, race, 2 or 3 vessel 
disease, left ventricular ejection fraction, involvement or not of left anterior descending artery, 
history of stroke, renal insufficiency, glycated hemoglobin < 7 or ≥ 7%, or SYNTAX score.  The SYNTAX 
score grades the angiographic lesion complexity of coronary disease to higher, intermediate, or 
lower levels. 
Major bleeding in the first 30 days occurred in more subjects in the CABG (34 subjects) than in the 
PCI group (23), although this difference was not significant.  Also more subjects in the CABG (8 
subjects) than in the PCI group (1) had acute kidney failure requiring hemodialysis in the 30 days, 
and this a significant difference.  
3. Real world diabetic population from a Registry 
3.1 Method and results 
The methods and results showing that CABG has advantages over PCI in subjects with diabetes in a 
real world population are summarised in this section [8].  The Italian region of Emilia-Romagna, with 
a population of 4 million, keeps a Registry of subjects undergoing CABG and PCI.  From this Registry, 
between July 2002- December 2008, subjects were selected who had left main coronary disease or 
at least two other coronary arteries with disease who were treated with CABG or PCI.  Subjects were 
excluded if they had previously undergone revascularization or had recent ST-elevation myocardial 
infarction.   
Of the subjects who were diabetic, 1419 had CABG and 1466 PCI.  The groups were not well 
matched. In the PCI group, there were less subjects, as a percentage of the total number of subjects 
having a PCI, in the age range 61-75 years (PCI, 50%; CABG, 62%), but more subjects > 75 years old 
had a PCI (31% vs 19%).  In the PCI group, there were more subjects with 2-3 diseased vessels 
without the left main coronary artery (86.8%) than in the CABG group (56.7%), which meant there 
were less subjects with 2/3 diseased vessel with the left main coronary artery in the PCI (9.3%) than 
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CABG group (41.8).  Previous myocardial infarction was more common in the PCI than CABG group 
(41% vs 23%).   
As a consequence of these differences between groups, a matching process based on estimated 
propensity score was undertaken, and produced 734 subjects with diabetes for each group. In the 
PCI group, 377/51% in the CABG group 629/86% had complete revascularization.   
After 5 years, the mortality rate for subjects with diabetes was significantly lower with CABG (18%) 
than with PCI (25%).  Also, significantly lower with CABG was acute myocardial infarction (5.8% vs 
18.1%), and treated vessel revascularization (8% vs 30.2%), but there was no difference in the rate of 
stroke between CABG (5.7%) and PCI (4.8%). 
In the PCI group, 266 subjects with diabetes had drug-eluting stents.  When CABG was compared to 
drug-eluting stents (predominantly sirolimus, followed by paclitaxel), mortality remained lower with 
CABG (18%) than with drug-eluting stents (25%).  Also, CABG was lower than drug-eluting stents for 
acute myocardial infarction (5.8% vs 22%) and treated vessel revascularization (10.4% vs 30.2%), but 
again, there was no difference in stroke between CABG and drug-eluting stents (5.7% vs 4.8%). 
3.2 Discussion 
The authors acknowledge that a limitation of the study is that it is an observational non-randomized 
study [8].  However, all outcome measures were in favor of CABG over PCI in subjects with diabetes, 
and the authors consider that this finding should be discussed with subjects with diabetes as part of 
informed consent [8].   
4. Expert Opinion 
4.1 Cost effectiveness 
FREEDOM clearly shows more benefits than detrimental effects of CABG over PCI in subjects with 
type 2 diabetes and coronary artery disease requiring revascularization [7].  Interestingly, the cost-
effectiveness comparison of CABG and PCI in the FREEDOM trial has been recently reported [9].  The 
CABG procedure was cheaper than PCI, but subjects stay in hospital longer after CABG than PCI, and 
this makes the combined cost higher for CABG than PCI [9].  Although the follow-up costs were 
greater with PCI due to more revascularizations, after five years, the overall costs for CABG were still 
higher than for PCI [9].  However, the projections over a lifetime were that the cost-effectiveness 
would favour CABG over PCI in subjects with type 2 diabetes and multivessel coronary artery 
disease, as there would be increased life expectancy, and quality-adjusted life expectancy [9].  Thus, 
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long-term, CABG may be more cost-effective than PCI in subjects with type 2 diabetes and coronary 
artery disease requiring revascularization. 
4.2 SYNTAX score 
Both the SYNTAX trial [3] and FREEDOM [7] investigated the relationship between SYNTAX score and 
the composite outcome of death, myocardial infarction and stroke.  After 3 years, the SYNTAX trial 
reported no significant differences between this composite for PCI and CABG, for scores 0-22, 23-32 
and ≥ 33 [3].  After 5 years, FREEDOM showed a significant benefit of CABG over PCI for these 3 
ranges of scores [7].   Close examination suggests that this data is not inconsistent, and may just 
represent different time points and population size.  Thus, comparing the data after 3 years (from 
Figure 3 in the appendix of FREEDOM) and SYNTAX, there seems to be no benefit of CABG over PCI in 
subjects with scores of 0-22 in FREEDOM [7].  The graphs from FREEDOM do suggest a benefit of 
CABG over PCI at 3 years for the higher SYNTAX scores [7].  However, this is not wholly inconsistent 
with the SYNTAX trial, which also has fewer subjects with this composite outcome in the CABG than 
PCI group, although this is not significant [3].   As SYNTAX had a smaller number of subjects than 
FREEDOM, it will have less power to detect significant differences between PCI and CABG. 
4.3 Improving stroke outcomes 
If CABG is going to be preferred to PCI in subjects with type 2 diabetes and multivessel disease, 
attention should be given to the stroke rates with CABG.  In FREEDOM, over the first 30 days, the 
primary outcome occurred less with PCI than CABG in subjects with type 2 diabetes and multivessel 
disease [7].  There is no breakdown in the paper of which component/s of the primary outcome 
(death, myocardial infarction or stroke) was/were higher with CABG at this time.  However, Figure 
1B suggests that death, and Figure 2A in the appendix suggests that myocardial infarction was 
similar in the PCI and CABG groups after 30 days, but Figure 2B in the appendix suggests that stroke 
was higher with CABG than PCI after 30 days.  The FREEDOM paper does provide information on 
stroke after 2 and 5 years, when it also occurred less often with PCI than CABG [7].    
The difference in stroke rates may have been related to anti-platelet drug use.  Thus, thirty days 
after the procedure more subjects in the PCI group were using aspirin and a thienopyridine than in 
the CABG group; aspirin, 99.1 vs 88.4%; thienopyridine, 98.4 vs 24.6%; and this greater use of anti-
platelet drugs after PCI, compared to CABG, was still apparent after 1 and 2 years [7].  However, it is 
not known whether the greater anti-platelet drug use after PCI contributed to the lesser incidence of 
stroke with PCI than CABG in FREEDOM, and this needs to be considered. 
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In the Registry study, there was no significant difference in the stroke rates, although strokes were 
lower with PCI (4.8%) than CABG (5.7%) [8].  This lack of significance may be related to lower 
number of subjects in the Registry study, and thus, a lesser power to detect significant difference. 
4.4 Real or not real populations 
Usually, randomized trials (e.g. FREEDOM) are considered to contain much higher levels of proof 
than non-randomized trial e.g. the Registry study discussed in section 3.  However, it is possible that 
the population in the Registry study was more real than in FREEDOM.  Thus, only 57% of subjects 
who were eligible consented to FREEDOM [7], and the population enrolled may not have been 
representative of the population having PCI or CABG.  FREEDOM was also confined to major 
hospitals within the US and Canada.  In contrast, the Registry study did have a real population from 
all centres with interventional cardiology and open-heart facilities within a region of Italy [8].  Thus, 
it is worth considering both studies, and it is encouraging that both have similar conclusions i.e. less 
death, myocardial infarction, and revascularization with CABG than PCI in subjects with type 2 
diabetes. 
4.5 Conclusions  
Long-term results of two recent studies (FREEDOM and a Registry study) show that in subjects with 
type 2 diabetes and multivessel coronary disease, CABG is more beneficial than PCI, as there is less 
revascularization, death and myocardial infarction.  However, the rates of stroke may be higher with 
CABG than PCI in this population.  Thus, if CABG is going to be preferred to PCI in subjects with type 
2 diabetes and multivessel coronary disease, consideration should be given to how to reduce the 
rates of stroke.  
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